Top

Current Allergy and Asthma Reports

Published in:

01-07-2020 | Omalizumab | Pediatric Allergy and Immunology (W Dolen, Section Editor)

Monoclonal Antibody Therapy in Childhood Asthma

Authors: Katherine L. Tison, Meera Patrawala, Michael S. Blaiss

Published in: Current Allergy and Asthma Reports | Issue 7/2020

Abstract

Purpose of Review

There has been an explosion of monoclonal antibodies in the treatment of severe uncontrolled adult asthma. Studies have now been published in severe pediatric asthma. There are numerous questions that need to be answered in determining whether these modalities are appropriate and safe in children.

Recent Findings

This is a narrative review examining the latest pediatric literature on monoclonal antibodies, both approved and in the pipeline, for uncontrolled asthma. Presently, all of the biologics are positioned to treat patients with underlying type 2 high disease. Two monoclonal antibodies are approved for children 6 years of age and older, omalizumab and mepolizumab, with more likely approved in the near future.

Summary

The effect of these agents in controlling severe pediatric asthma is promising. Data is limited to long-term efficacy and safety, and whether any agent has an effect on the natural history of asthma.

Black LI BV. Tables of Summary Health Statistics for U.S. Children: 2018 National Health Interview Survey. Table C-1. 2019.

Zahran HS, Bailey CM, Damon SA, Garbe PL, Breysse PN. Vital signs: asthma in children - United States, 2001–2016. MMWR Morb Mortal Wkly Rep. 2018;67(5):149–55. https://doi.org/10.15585/mmwr.mm6705e1.CrossRefPubMedCentral

Guilbert TW, Bacharier LB, Fitzpatrick AM. Severe asthma in children. J Allergy Clin Immunol Pract. 2014;2(5):489–500. https://doi.org/10.1016/j.jaip.2014.06.022.CrossRefPubMedCentral

Buelo A, McLean S, Julious S, Flores-Kim J, Bush A, Henderson J, et al. At-risk children with asthma (ARC): a systematic review. Thorax. 2018;73(9):813–24. https://doi.org/10.1136/thoraxjnl-2017-210939.CrossRefPubMedCentral

Blaiss MS, Castro M, Chipps BE, Zitt M, Panettieri RA Jr, Foggs MB. Guiding principles for use of newer biologics and bronchial thermoplasty for patients with severe asthma. Ann Allergy Asthma Immunol. 2017;119(6):533–40. https://doi.org/10.1016/j.anai.2017.09.058.CrossRef

•• Kuruvilla ME, Lee FE, Lee GB. Understanding asthma phenotypes, endotypes, and mechanisms of disease. Clin Rev Allergy Immunol. 2019;56(2):219–33. https://doi.org/10.1007/s12016-018-8712-1. Clear and concise update on phenotypes and endotypes in asthma. CrossRefPubMedCentral

Gauthier M, Ray A, Wenzel SE. Evolving concepts of asthma. Am J Respir Crit Care Med. 2015;192(6):660–8. https://doi.org/10.1164/rccm.201504-0763PP.CrossRefPubMedCentral

Bush A. Pathophysiological mechanisms of asthma. Front Pediatr. 2019;7:68. https://doi.org/10.3389/fped.2019.00068.CrossRefPubMedCentral

Woodruff PG, Modrek B, Choy DF, Jia G, Abbas AR, Ellwanger A, et al. T-helper type 2-driven inflammation defines major subphenotypes of asthma. Am J Respir Crit Care Med. 2009;180(5):388–95. https://doi.org/10.1164/rccm.200903-0392OC.CrossRefPubMedCentral

10.

Johansson SG, Hourihane JO, Bousquet J, Bruijnzeel-Koomen C, Dreborg S, Haahtela T, et al. A revised nomenclature for allergy. An EAACI position statement from the EAACI nomenclature task force. Allergy. 2001;56(9):813–24. https://doi.org/10.1034/j.1398-9995.2001.t01-1-00001.x.CrossRef

11.

Lambrecht BN, Hammad H. The immunology of asthma. Nat Immunol. 2015;16(1):45–56. https://doi.org/10.1038/ni.3049.CrossRef

12.

Licari A, Castagnoli R, Brambilla I, Marseglia A, Tosca MA, Marseglia GL, et al. Asthma endotyping and biomarkers in childhood asthma. Pediatr Allergy Immunol Pulmonol. 2018;31(2):44–55. https://doi.org/10.1089/ped.2018.0886.CrossRefPubMedCentral

13.

Price DB, Rigazio A, Campbell JD, Bleecker ER, Corrigan CJ, Thomas M, et al. Blood eosinophil count and prospective annual asthma disease burden: a UK cohort study. Lancet Respir Med. 2015;3(11):849–58. https://doi.org/10.1016/s2213-2600(15)00367-7.CrossRef

14.

Israel E, Reddel HK. Severe and difficult-to-treat asthma in adults. N Engl J Med. 2017;377(10):965–76. https://doi.org/10.1056/NEJMra1608969.CrossRef

15.

Korevaar DA, Westerhof GA, Wang J, Cohen JF, Spijker R, Sterk PJ, et al. Diagnostic accuracy of minimally invasive markers for detection of airway eosinophilia in asthma: a systematic review and meta-analysis. Lancet Respir Med. 2015;3(4):290–300. https://doi.org/10.1016/s2213-2600(15)00050-8.CrossRef

16.

•• Busse WW. Biological treatments for severe asthma: a major advance in asthma care. Allergol Int. 2019;68(2):158–66. https://doi.org/10.1016/j.alit.2019.01.004. An excellent review in understanding the roles of biologics in management of severe asthma. CrossRef

17.

Akar-Ghibril N, Casale T, Custovic A, Phipatanakul W. Allergic endotypes and phenotypes of asthma. J Allergy Clin Immunol Pract. 2020;8(2):429–40. https://doi.org/10.1016/j.jaip.2019.11.008.CrossRef

18.

Fitzpatrick AM, Jackson DJ, Mauger DT, Boehmer SJ, Phipatanakul W, Sheehan WJ, et al. Individualized therapy for persistent asthma in young children. J Allergy Clin Immunol. 2016;138(6):1608–18.e12. https://doi.org/10.1016/j.jaci.2016.09.028.CrossRefPubMedCentral

19.

Siroux V, Oryszczyn MP, Paty E, Kauffmann F, Pison C, Vervloet D, et al. Relationships of allergic sensitization, total immunoglobulin E and blood eosinophils to asthma severity in children of the EGEA study. Clin Exp Allergy. 2003;33(6):746–51. https://doi.org/10.1046/j.1365-2222.2003.01674.x.CrossRef

20.

Fitzpatrick AM, Gaston BM, Erzurum SC, Teague WG. Features of severe asthma in school-age children: atopy and increased exhaled nitric oxide. J Allergy Clin Immunol. 2006;118(6):1218–25. https://doi.org/10.1016/j.jaci.2006.08.019.CrossRefPubMedCentral

21.

Chibana K, Trudeau JB, Mustovich AT, Hu H, Zhao J, Balzar S, et al. IL-13 induced increases in nitrite levels are primarily driven by increases in inducible nitric oxide synthase as compared with effects on arginases in human primary bronchial epithelial cells. Clin Exp Allergy. 2008;38(6):936–46. https://doi.org/10.1111/j.1365-2222.2008.02969.x.CrossRef

22.

Dweik RA, Boggs PB, Erzurum SC, Irvin CG, Leigh MW, Lundberg JO, et al. An official ATS clinical practice guideline: interpretation of exhaled nitric oxide levels (FENO) for clinical applications. Am J Respir Crit Care Med. 2011;184(5):602–15. https://doi.org/10.1164/rccm.9120-11ST.CrossRefPubMedCentral

23.

Dweik RA, Sorkness RL, Wenzel S, Hammel J, Curran-Everett D, Comhair SA, et al. Use of exhaled nitric oxide measurement to identify a reactive, at-risk phenotype among patients with asthma. Am J Respir Crit Care Med. 2010;181(10):1033–41. https://doi.org/10.1164/rccm.200905-0695OC.CrossRefPubMedCentral

24.

Petsky HL, Cates CJ, Kew KM, Chang AB. Tailoring asthma treatment on eosinophilic markers (exhaled nitric oxide or sputum eosinophils): a systematic review and meta-analysis. Thorax. 2018;73(12):1110–9. https://doi.org/10.1136/thoraxjnl-2018-211540.CrossRef

25.

Bossley CJ, Fleming L, Gupta A, Regamey N, Frith J, Oates T, et al. Pediatric severe asthma is characterized by eosinophilia and remodeling without T(H)2 cytokines. J Allergy Clin Immunol. 2012;129(4):974–82.e13. https://doi.org/10.1016/j.jaci.2012.01.059.CrossRefPubMedCentral

26.

Samitas K, Zervas E, Gaga M. T2-low asthma: current approach to diagnosis and therapy. Curr Opin Pulm Med. 2017;23(1):48–55. https://doi.org/10.1097/mcp.0000000000000342.CrossRef

27.

Wang F, He XY, Baines KJ, Gunawardhana LP, Simpson JL, Li F, et al. Different inflammatory phenotypes in adults and children with acute asthma. Eur Respir J. 2011;38(3):567–74. https://doi.org/10.1183/09031936.00170110.CrossRef

28.

Just J, Bourgoin-Heck M, Amat F. Clinical phenotypes in asthma during childhood. Clin Exp Allergy. 2017;47(7):848–55. https://doi.org/10.1111/cea.12939.CrossRef

29.

Just J, Gouvis-Echraghi R, Couderc R, Guillemot-Lambert N, Saint-Pierre P. Novel severe wheezy young children phenotypes: boys atopic multiple-trigger and girls nonatopic uncontrolled wheeze. J Allergy Clin Immunol. 2012;130(1):103–10.e8. https://doi.org/10.1016/j.jaci.2012.02.041.CrossRef

30.

Wood LG, Baines KJ, Fu J, Scott HA, Gibson PG. The neutrophilic inflammatory phenotype is associated with systemic inflammation in asthma. Chest. 2012;142(1):86–93. https://doi.org/10.1378/chest.11-1838.CrossRef

31.

Fajt ML, Wenzel SE. Asthma phenotypes and the use of biologic medications in asthma and allergic disease: the next steps toward personalized care. J Allergy Clin Immunol. 2015;135(2):299–310; quiz 1. https://doi.org/10.1016/j.jaci.2014.12.1871.CrossRef

32.

Bozzetto S, Carraro S, Zanconato S, Baraldi E. Severe asthma in childhood: diagnostic and management challenges. Curr Opin Pulm Med. 2015;21(1):16–21. https://doi.org/10.1097/mcp.0000000000000121.CrossRef

33.

Bender BG, Pedan A, Varasteh LT. Adherence and persistence with fluticasone propionate/salmeterol combination therapy. J Allergy Clin Immunol. 2006;118(4):899–904. https://doi.org/10.1016/j.jaci.2006.07.002.CrossRef

34.

Berger W, Gupta N, McAlary M, Fowler-Taylor A. Evaluation of long-term safety of the anti-IgE antibody, omalizumab, in children with allergic asthma. Ann Allergy Asthma Immunol. 2003;91(2):182–8. https://doi.org/10.1016/s1081-1206(10)62175-8.CrossRef

35.

Brodlie M, McKean MC, Moss S, Spencer DA. The oral corticosteroid-sparing effect of omalizumab in children with severe asthma. Arch Dis Child. 2012;97(7):604–9. https://doi.org/10.1136/archdischild-2011-301570.CrossRef

36.

Busse WW, Morgan WJ, Gergen PJ, Mitchell HE, Gern JE, Liu AH, et al. Randomized trial of omalizumab (anti-IgE) for asthma in inner-city children. N Engl J Med. 2011;364(11):1005–15. https://doi.org/10.1056/NEJMoa1009705.CrossRefPubMedCentral

37.

•• Busse WW, Haselkorn T, Rosén K, Trzaskoma BL, Ortiz B, Szefler SJ. Greater treatment benefit with omalizumab in children with increased asthma severity: exploratory analyses from the Inner-City Anti-IgE Therapy for Asthma (ICATA) Study. J Allergy Clin Immunol. 2018a;141(2):AB14. https://doi.org/10.1016/j.jaci.2017.12.045. Further analysis of the role of omalizumab in inner-city children with asthma. CrossRef

38.

Busse W, Buhl R, Fernandez Vidaurre C, Blogg M, Zhu J, Eisner MD, et al. Omalizumab and the risk of malignancy: results from a pooled analysis. J Allergy Clin Immunol. 2012;129(4):983–9.e6. https://doi.org/10.1016/j.jaci.2012.01.033.CrossRef

39.

Deschildre A, Marguet C, Salleron J, Pin I, Rittie JL, Derelle J, et al. Add-on omalizumab in children with severe allergic asthma: a 1-year real life survey. Eur Respir J. 2013;42(5):1224–33. https://doi.org/10.1183/09031936.00149812.CrossRef

40.

Deschildre A, Marguet C, Langlois C, Pin I, Rittie JL, Derelle J, et al. Real-life long-term omalizumab therapy in children with severe allergic asthma. Eur Respir J. 2015;46(3):856–9. https://doi.org/10.1183/09031936.00008115.CrossRef

41.

Deschildre A, Roussel J, Drumez E, Abou-Taam R, Rames C, Le Roux P, et al. Omalizumab discontinuation in children with severe allergic asthma: an observational real-life study. Allergy. 2019;74(5):999–1003. https://doi.org/10.1111/all.13678.CrossRef

42.

Hanania NA, Alpan O, Hamilos DL, Condemi JJ, Reyes-Rivera I, Zhu J, et al. Omalizumab in severe allergic asthma inadequately controlled with standard therapy: a randomized trial. Ann Intern Med. 2011;154(9):573–82. https://doi.org/10.7326/0003-4819-154-9-201105030-00002.CrossRef

43.

Hanania NA, Wenzel S, Rosen K, Hsieh HJ, Mosesova S, Choy DF, et al. Exploring the effects of omalizumab in allergic asthma: an analysis of biomarkers in the EXTRA study. Am J Respir Crit Care Med. 2013;187(8):804–11. https://doi.org/10.1164/rccm.201208-1414OC.CrossRef

44.

Kulus M, Hebert J, Garcia E, Fowler Taylor A, Fernandez Vidaurre C, Blogg M. Omalizumab in children with inadequately controlled severe allergic (IgE-mediated) asthma. Curr Med Res Opin. 2010;26(6):1285–93. https://doi.org/10.1185/03007991003771338.CrossRef

45.

Lanier B, Bridges T, Kulus M, Taylor AF, Berhane I, Vidaurre CF. Omalizumab for the treatment of exacerbations in children with inadequately controlled allergic (IgE-mediated) asthma. J Allergy Clin Immunol. 2009;124(6):1210–6. https://doi.org/10.1016/j.jaci.2009.09.021.CrossRef

46.

Lemanske RF Jr, Nayak A, McAlary M, Everhard F, Fowler-Taylor A, Gupta N. Omalizumab improves asthma-related quality of life in children with allergic asthma. Pediatrics. 2002;110(5):e55. https://doi.org/10.1542/peds.110.5.e55.CrossRef

47.

Milgrom H, Berger W, Nayak A, Gupta N, Pollard S, McAlary M, et al. Treatment of childhood asthma with anti-immunoglobulin E antibody (omalizumab). Pediatrics. 2001;108(2):E36. https://doi.org/10.1542/peds.108.2.e36.CrossRef

48.

Milgrom H, Fowler-Taylor A, Vidaurre CF, Jayawardene S. Safety and tolerability of omalizumab in children with allergic (IgE-mediated) asthma. Curr Med Res Opin. 2011;27(1):163–9. https://doi.org/10.1185/03007995.2010.539502.CrossRef

49.

Silkoff PE, Romero FA, Gupta N, Townley RG, Milgrom H. Exhaled nitric oxide in children with asthma receiving Xolair (omalizumab), a monoclonal anti-immunoglobulin E antibody. Pediatrics. 2004;113(4):e308–12. https://doi.org/10.1542/peds.113.4.e308.CrossRef

50.

Teach SJ, Gill MA, Togias A, Sorkness CA, Arbes SJ Jr, Calatroni A, et al. Preseasonal treatment with either omalizumab or an inhaled corticosteroid boost to prevent fall asthma exacerbations. J Allergy Clin Immunol. 2015;136(6):1476–85. https://doi.org/10.1016/j.jaci.2015.09.008.CrossRefPubMedCentral

51.

Gupta A, Pouliquen I, Austin D, Price RG, Kempsford R, Steinfeld J, et al. Subcutaneous mepolizumab in children aged 6 to 11 years with severe eosinophilic asthma. Pediatr Pulmonol. 2019a;54(12):1957–67. https://doi.org/10.1002/ppul.24508.CrossRefPubMedCentral

52.

Gupta A, Ikeda M, Geng B, Azmi J, Price RG, Bradford ES, et al. Long-term safety and pharmacodynamics of mepolizumab in children with severe asthma with an eosinophilic phenotype. J Allergy Clin Immunol. 2019b;144(5):1336–42.e7. https://doi.org/10.1016/j.jaci.2019.08.005.CrossRef

53.

Bleecker ER, FitzGerald JM, Chanez P, Papi A, Weinstein SF, Barker P, et al. Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting beta2-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial. Lancet. 2016a;388(10056):2115–27. https://doi.org/10.1016/s0140-6736(16)31324-1.CrossRef

54.

Ferguson GT, FitzGerald JM, Bleecker ER, Laviolette M, Bernstein D, LaForce C, et al. Benralizumab for patients with mild to moderate, persistent asthma (BISE): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Respir Med. 2017a;5(7):568–76. https://doi.org/10.1016/s2213-2600(17)30190-x.CrossRef

55.

FitzGerald JM, Bleecker ER, Nair P, Korn S, Ohta K, Lommatzsch M, et al. Benralizumab, an anti-interleukin-5 receptor alpha monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2016a;388(10056):2128–41. https://doi.org/10.1016/s0140-6736(16)31322-8.CrossRef

56.

Busse WW, Maspero JF, Rabe KF, Papi A, Wenzel SE, Ford LB, et al. Liberty asthma QUEST: phase 3 randomized, double-blind, placebo-controlled, parallel-group study to evaluate dupilumab efficacy/safety in patients with uncontrolled. Moderate-to-Severe Asthma Adv Ther. 2018b;35(5):737–48. https://doi.org/10.1007/s12325-018-0702-4.CrossRef

57.

Castro M, Corren J, Pavord ID, Maspero J, Wenzel S, Rabe KF, et al. Dupilumab efficacy and safety in moderate-to-severe uncontrolled asthma. N Engl J Med. 2018;378(26):2486–96. https://doi.org/10.1056/NEJMoa1804092.CrossRef

58.

Corren J, Castro M, Chanez P, Fabbri L, Joish VN, Amin N, et al. Dupilumab improves symptoms, quality of life, and productivity in uncontrolled persistent asthma. Ann Allergy Asthma Immunol. 2019;122(1):41–9.e2. https://doi.org/10.1016/j.anai.2018.08.005.CrossRef

59.

Corren J, Castro M, O'Riordan T, Hanania NA, Pavord ID, Quirce S, et al. Dupilumab efficacy in patients with uncontrolled, moderate-to-severe allergic asthma. J Allergy Clin Immunol Pract. 2020;8(2):516–26. https://doi.org/10.1016/j.jaip.2019.08.050.CrossRef

60.

Rabe KF, Nair P, Brusselle G, Maspero JF, Castro M, Sher L, et al. Efficacy and safety of dupilumab in glucocorticoid-dependent severe asthma. N Engl J Med. 2018;378(26):2475–85. https://doi.org/10.1056/NEJMoa1804093.CrossRef

61.

Schulman ES. Development of a monoclonal anti-immunoglobulin E antibody (omalizumab) for the treatment of allergic respiratory disorders. Am J Respir Crit Care Med. 2001;164(8 Pt 2):S6–11. https://doi.org/10.1164/ajrccm.164.supplement_1.2103025.CrossRef

62.

Holgate S, Casale T, Wenzel S, Bousquet J, Deniz Y, Reisner C. The anti-inflammatory effects of omalizumab confirm the central role of IgE in allergic inflammation. J Allergy Clin Immunol. 2005;115(3):459–65. https://doi.org/10.1016/j.jaci.2004.11.053.CrossRef

63.

Prussin C, Griffith DT, Boesel KM, Lin H, Foster B, Casale TB. Omalizumab treatment downregulates dendritic cell FcepsilonRI expression. J Allergy Clin Immunol. 2003;112(6):1147–54. https://doi.org/10.1016/j.jaci.2003.10.003.CrossRef

64.

Licari A, Castagnoli R, Panfili E, Marseglia A, Brambilla I, Marseglia GL. An update on anti-IgE therapy in pediatric respiratory diseases. Curr Respir Med Rev. 2017;13(1):22–9. https://doi.org/10.2174/1573398x13666170616110738.CrossRefPubMedCentral

65.

Djukanovic R, Wilson SJ, Kraft M, Jarjour NN, Steel M, Chung KF, et al. Effects of treatment with anti-immunoglobulin E antibody omalizumab on airway inflammation in allergic asthma. Am J Respir Crit Care Med. 2004;170(6):583–93. https://doi.org/10.1164/rccm.200312-1651OC.CrossRef

66.

Holgate S, Smith N, Massanari M, Jimenez P. Effects of omalizumab on markers of inflammation in patients with allergic asthma. Allergy. 2009;64(12):1728–36. https://doi.org/10.1111/j.1398-9995.2009.02201.x.CrossRef

67.

Gill MA, Bajwa G, George TA, Dong CC, Dougherty II, Jiang N, et al. Counterregulation between the FcepsilonRI pathway and antiviral responses in human plasmacytoid dendritic cells. J Immunol. 2010;184(11):5999–6006. https://doi.org/10.4049/jimmunol.0901194.CrossRefPubMedCentral

68.

Durrani SR, Montville DJ, Pratt AS, Sahu S, DeVries MK, Rajamanickam V, et al. Innate immune responses to rhinovirus are reduced by the high-affinity IgE receptor in allergic asthmatic children. J Allergy Clin Immunol. 2012;130(2):489–95. https://doi.org/10.1016/j.jaci.2012.05.023.CrossRefPubMedCentral

69.

Cardet JC, Casale TB. New insights into the utility of omalizumab. J Allergy Clin Immunol. 2019;143(3):923–6.e1. https://doi.org/10.1016/j.jaci.2019.01.016.CrossRefPubMedCentral

70.

Rodrigo GJ, Neffen H. Systematic review on the use of omalizumab for the treatment of asthmatic children and adolescents. Pediatr Allergy Immunol. 2015;26(6):551–6. https://doi.org/10.1111/pai.12405.CrossRef

71.

Hill DA, Siracusa MC, Ruymann KR, Tait Wojno ED, Artis D, Spergel JM. Omalizumab therapy is associated with reduced circulating basophil populations in asthmatic children. Allergy. 2014;69(5):674–7. https://doi.org/10.1111/all.12375.CrossRefPubMedCentral

72.

Genentech I. Omalizumab prescribing information. https://www.gene.com/download/pdf/xolair_prescribing.pdf. Accessed 25 Feb 2020.

73.

Soler M, Matz J, Townley R, Buhl R, O'Brien J, Fox H, et al. The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics. Eur Respir J. 2001;18(2):254–61. https://doi.org/10.1183/09031936.01.00092101.CrossRef

74.

Busse W, Corren J, Lanier BQ, McAlary M, Fowler-Taylor A, Cioppa GD, et al. Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma. J Allergy Clin Immunol. 2001;108(2):184–90. https://doi.org/10.1067/mai.2001.117880.CrossRef

75.

Licari A, Manti S, Castagnoli R, Marseglia A, Foiadelli T, Brambilla I, et al. Immunomodulation in pediatric asthma. Front Pediatr. 2019;7:289. https://doi.org/10.3389/fped.2019.00289.CrossRefPubMedCentral

76.

Licari A, Marseglia G, Castagnoli R, Marseglia A, Ciprandi G. The discovery and development of omalizumab for the treatment of asthma. Expert Opin Drug Discov. 2015;10(9):1033–42. https://doi.org/10.1517/17460441.2015.1048220.CrossRef

77.

Licari A, Marseglia A, Caimmi S, Castagnoli R, Foiadelli T, Barberi S, et al. Omalizumab in children. Paediatr Drugs. 2014;16(6):491–502. https://doi.org/10.1007/s40272-014-0107-z.CrossRefPubMedCentral

78.

•• Chipps BE, Lanier B, Milgrom H, Deschildre A, Hedlin G, Szefler SJ, et al. Omalizumab in children with uncontrolled allergic asthma: review of clinical trial and real-world experience. J Allergy Clin Immunol. 2017;139(5):1431–44. https://doi.org/10.1016/j.jaci.2017.03.002. Excellent overview covering the role of omalizumab in pediatric asthma. CrossRef

79.

Food and Drug Administration. 2015. https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2016/103976Orig1s5225ltr.pdf. Accessed 25 Feb 2020.

80.

Johnston NW, Johnston SL, Norman GR, Dai J, Sears MR. The September epidemic of asthma hospitalization: school children as disease vectors. J Allergy Clin Immunol. 2006;117(3):557–62. https://doi.org/10.1016/j.jaci.2005.11.034.CrossRef

81.

Normansell R, Walker S, Milan SJ, Walters EH, Nair P. Omalizumab for asthma in adults and children. Cochrane Database Syst Rev. 2014;(1):Cd003559. https://doi.org/10.1002/14651858.CD003559.pub4.

82.

Hendeles L, Khan YR, Shuster JJ, Chesrown SE, Abu-Hasan M. Omalizumab therapy for asthma patients with poor adherence to inhaled corticosteroid therapy. Ann Allergy Asthma Immunol. 2015;114(1):58–62.e2. https://doi.org/10.1016/j.anai.2014.10.012.CrossRefPubMedCentral

83.

Pitrez PM, de Souza RG, Roncada C, Heinzmann-Filho JP, Santos G, Pinto LA, et al. Impact of omalizumab in children from a middle-income country with severe therapy-resistant asthma: a real-life study. Pediatr Pulmonol. 2017;52(11):1408–13. https://doi.org/10.1002/ppul.23845.CrossRef

84.

Long A, Rahmaoui A, Rothman KJ, Guinan E, Eisner M, Bradley MS, et al. Incidence of malignancy in patients with moderate-to-severe asthma treated with or without omalizumab. J Allergy Clin Immunol. 2014;134(3):560–7.e4. https://doi.org/10.1016/j.jaci.2014.02.007.CrossRef

85.

Sese L, Schneider M, Bourgoin M, Saint-Pierre P, Lambert N, Guiddir T, et al. Asthma with multiple allergic comorbidities is associated with complete response to omalizumab. Clin Exp Allergy. 2019;49(5):733–5. https://doi.org/10.1111/cea.13373.CrossRef

86.

Bourgoin-Heck M, Amat F, Trouve C, Bernard A, Magny JP, Lambert N, et al. Omalizumab could be effective in children with severe eosinophilic non-allergic asthma. Pediatr Allergy Immunol. 2018;29(1):90–3. https://doi.org/10.1111/pai.12813.CrossRef

87.

Preventing Asthma in High Risk Kids (PARK). https://clinicaltrials.gov/ct2/show/NCT02570984?term=preventing+asthma+in+high+risk+kids&draw=2&rank=1. Accessed 25 Feb 2020.

88.

Iftikhar IH, Schimmel M, Bender W, Swenson C, Amrol D. Comparative efficacy of anti IL-4, IL-5 and IL-13 drugs for treatment of eosinophilic asthma: a network meta-analysis. Lung. 2018;196(5):517–30. https://doi.org/10.1007/s00408-018-0151-5.CrossRef

89.

Carr TF, Zeki AA, Kraft M. Eosinophilic and noneosinophilic asthma. Am J Respir Crit Care Med. 2018;197(1):22–37. https://doi.org/10.1164/rccm.201611-2232PP.CrossRefPubMedCentral

90.

Busse W, Chupp G, Nagase H, Albers FC, Doyle S, Shen Q, et al. Anti-IL-5 treatments in patients with severe asthma by blood eosinophil thresholds: indirect treatment comparison. J Allergy Clin Immunol. 2019;143(1):190–200.e20. https://doi.org/10.1016/j.jaci.2018.08.031.CrossRef

91.

Bel EH, Wenzel SE, Thompson PJ, Prazma CM, Keene ON, Yancey SW, et al. Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma. N Engl J Med. 2014;371(13):1189–97. https://doi.org/10.1056/NEJMoa1403291.CrossRef

92.

Lugogo N, Domingo C, Chanez P, Leigh R, Gilson MJ, Price RG, et al. Long-term efficacy and safety of mepolizumab in patients with severe eosinophilic asthma: a multi-center, open-label, phase IIIb study. Clin Ther. 2016;38(9):2058–70.e1. https://doi.org/10.1016/j.clinthera.2016.07.010.CrossRef

93.

Ortega HG, Liu MC, Pavord ID, Brusselle GG, FitzGerald JM, Chetta A, et al. Mepolizumab treatment in patients with severe eosinophilic asthma. N Engl J Med. 2014;371(13):1198–207. https://doi.org/10.1056/NEJMoa1403290.CrossRef

94.

Chupp GL, Bradford ES, Albers FC, Bratton DJ, Wang-Jairaj J, Nelsen LM, et al. Efficacy of mepolizumab add-on therapy on health-related quality of life and markers of asthma control in severe eosinophilic asthma (MUSCA): a randomised, double-blind, placebo-controlled, parallel-group, multicentre, phase 3b trial. Lancet Respir Med. 2017;5(5):390–400. https://doi.org/10.1016/s2213-2600(17)30125-x.CrossRef

95.

Pham TH, Damera G, Newbold P, Ranade K. Reductions in eosinophil biomarkers by benralizumab in patients with asthma. Respir Med. 2016;111:21–9. https://doi.org/10.1016/j.rmed.2016.01.003.CrossRef

96.

Gandhi NA, Bennett BL, Graham NM, Pirozzi G, Stahl N, Yancopoulos GD. Targeting key proximal drivers of type 2 inflammation in disease. Nat Rev Drug Discov. 2016;15(1):35–50. https://doi.org/10.1038/nrd4624.CrossRef

97.

Doherty TA, Broide DH. Group 2 innate lymphoid cells: new players in human allergic diseases. J Investig Allergol Clin Immunol. 2015;25(1):1–11 quiz 2p following.PubMedCentral

98.

Vatrella A, Fabozzi I, Calabrese C, Maselli R, Pelaia G. Dupilumab: a novel treatment for asthma. J Asthma Allergy. 2014;7:123–30. https://doi.org/10.2147/jaa.S52387.CrossRefPubMedCentral

99.

Licona-Limon P, Kim LK, Palm NW, Flavell RA. TH2, allergy and group 2 innate lymphoid cells. Nat Immunol. 2013;14(6):536–42. https://doi.org/10.1038/ni.2617.CrossRef

100.

Steinke JW, Borish L. Th2 cytokines and asthma. Interleukin-4: its role in the pathogenesis of asthma, and targeting it for asthma treatment with interleukin-4 receptor antagonists. Respir Res. 2001;2(2):66–70. https://doi.org/10.1186/rr40.CrossRefPubMedCentral

101.

Corren J. Role of interleukin-13 in asthma. Curr Allergy Asthma Rep. 2013;13(5):415–20. https://doi.org/10.1007/s11882-013-0373-9.CrossRef

102.

Kau AL, Korenblat PE. Anti-interleukin 4 and 13 for asthma treatment in the era of endotypes. Curr Opin Allergy Clin Immunol. 2014;14(6):570–5. https://doi.org/10.1097/aci.0000000000000108.CrossRefPubMedCentral

103.

Rogliani P, Calzetta L, Matera MG, Laitano R, Ritondo BL, Hanania NA, et al. Severe asthma and biological therapy: when, which, and for whom. Pulm Ther. 2019. https://doi.org/10.1007/s41030-019-00109-1.

104.

Simpson EL, Paller AS, Siegfried EC, Boguniewicz M, Sher L, Gooderham MJ, et al. Efficacy and safety of dupilumab in adolescents with uncontrolled moderate to severe atopic dermatitis: a phase 3 randomized clinical trial. JAMA Dermatol. 2019;156:44. https://doi.org/10.1001/jamadermatol.2019.3336.CrossRefPubMedCentral

105.

Castro M, Zangrilli J, Wechsler ME, Bateman ED, Brusselle GG, Bardin P, et al. Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials. Lancet Respir Med. 2015;3(5):355–66. https://doi.org/10.1016/S2213-2600(15)00042-9.CrossRef

106.

Bjermer L, Lemiere C, Maspero J, Weiss S, Zangrilli J, Germinaro M. Reslizumab for inadequately controlled asthma with elevated blood eosinophil levels: a randomized phase 3 study. Chest. 2016;150(4):789–98. https://doi.org/10.1016/j.chest.2016.03.032.CrossRef

107.

Spergel JM, Rothenberg ME, Collins MH, Furuta GT, Markowitz JE, Fuchs G 3rd, et al. Reslizumab in children and adolescents with eosinophilic esophagitis: results of a double-blind, randomized, placebo-controlled trial. J Allergy Clin Immunol. 2012;129(2):456–63, 63.e1–3. https://doi.org/10.1016/j.jaci.2011.11.044.CrossRef

108.

Murphy K, Jacobs J, Bjermer L, Fahrenholz JM, Shalit Y, Garin M, et al. Long-term safety and efficacy of reslizumab in patients with eosinophilic asthma. J Allergy Clin Immunol Pract. 2017;5(6):1572–81.e3. https://doi.org/10.1016/j.jaip.2017.08.024.CrossRef

109.

Virchow JC, Katial R, Brusselle GG, Shalit Y, Garin M, McDonald M, et al. Safety of reslizumab in uncontrolled asthma with eosinophilia: a pooled analysis from 6 trials. J Allergy Clin Immunol Pract. 2020;8(2):540–8 e1. https://doi.org/10.1016/j.jaip.2019.07.038.CrossRef

110.

Ying S, O'Connor B, Ratoff J, Meng Q, Fang C, Cousins D, et al. Expression and cellular provenance of thymic stromal lymphopoietin and chemokines in patients with severe asthma and chronic obstructive pulmonary disease. J Immunol. 2008;181(4):2790–8. https://doi.org/10.4049/jimmunol.181.4.2790.CrossRef

111.

Ying S, O'Connor B, Ratoff J, Meng Q, Mallett K, Cousins D, et al. Thymic stromal lymphopoietin expression is increased in asthmatic airways and correlates with expression of Th2-attracting chemokines and disease severity. J Immunol. 2005;174(12):8183–90. https://doi.org/10.4049/jimmunol.174.12.8183.CrossRef

112.

Torgerson DG, Ampleford EJ, Chiu GY, Gauderman WJ, Gignoux CR, Graves PE, et al. Meta-analysis of genome-wide association studies of asthma in ethnically diverse North American populations. Nat Genet. 2011;43(9):887–92. https://doi.org/10.1038/ng.888.CrossRefPubMedCentral

113.

Chauhan A, Singh M, Agarwal A, Paul N. Correlation of TSLP, IL-33, and CD4 + CD25 + FOXP3 + T regulatory (Treg) in pediatric asthma. J Asthma. 2015;52(9):868–72. https://doi.org/10.3109/02770903.2015.1026441.CrossRef

114.

Gauvreau GM, O'Byrne PM, Boulet LP, Wang Y, Cockcroft D, Bigler J, et al. Effects of an anti-TSLP antibody on allergen-induced asthmatic responses. N Engl J Med. 2014;370(22):2102–10. https://doi.org/10.1056/NEJMoa1402895.CrossRef

115.

•• Corren J, Parnes JR, Wang L, Mo M, Roseti SL, Griffiths JM, et al. Tezepelumab in adults with uncontrolled asthma. N Engl J Med. 2017;377(10):936–46. https://doi.org/10.1056/NEJMoa1704064. Pivotal phase 2 study with tezepelumab that suggests in may benefit type 2 high and type 2 low asthma. CrossRef

116.

Zeiger RS, Schatz M, Dalal AA, Qian L, Chen W, Ngor EW, et al. Utilization and costs of severe uncontrolled asthma in a managed-care setting. J Allergy Clin Immunol Pract. 2016;4(1):120–9.e3. https://doi.org/10.1016/j.jaip.2015.08.003.CrossRef

117.

Barsky EE, Giancola LM, Baxi SN, Gaffin JM. A practical approach to severe asthma in children. Ann Am Thorac Soc. 2018;15(4):399–408. https://doi.org/10.1513/AnnalsATS.201708-637FR.CrossRefPubMedCentral

Title: Monoclonal Antibody Therapy in Childhood Asthma
Authors: Katherine L. Tison
Meera Patrawala
Michael S. Blaiss
Publication date: 01-07-2020
Publisher: Springer US
Keywords: Omalizumab
Bronchial Asthma
Mepolizumab
Reslizumab
Dupilumab
Published in: Current Allergy and Asthma Reports / Issue 7/2020
Print ISSN: 1529-7322
Electronic ISSN: 1534-6315
DOI: https://doi.org/10.1007/s11882-020-00919-3

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Monoclonal Antibody Therapy in Childhood Asthma

Abstract

Purpose of Review

Recent Findings

Summary

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Purpose of Review

Recent Findings

Summary

Please log in to get access to this content

Other articles of this Issue 7/2020

Effect of Functional Endoscopic Sinus Surgery on Outcomes in Chronic Rhinosinusitis​

Ligand Binding of PR-10 Proteins with a Particular Focus on the Bet v 1 Allergen Family

Phenotypes in Chronic Rhinosinusitis

Association Between Mouth Breathing and Asthma: a Systematic Review and Meta-analysis

Local Allergic Rhinitis Revisited

Extranasal Manifestations of Allergy in the Head and Neck

Effect of Functional Endoscopic Sinus Surgery on Outcomes in Chronic Rhinosinusitis